Sign up

Logos Global Management LP

$2.3B assets · 68 holdings · Q2 2026 · Filed 14 AUG 2026

About Logos Global Management LP’s 13F portfolio

Logos Global Management LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Logos Global Management LP reported $2.3B across 68 US-listed positions (). Its largest position is ERASCA INC (ERAS) at 9.6% of the reported book, and its ten biggest holdings make up 48% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$2.3B
Assets (13F)
#1,362
of 8,839 by size
68
Holdings
48%
Top-10 weight
43
Buys
39
Sells
Top holdings · Q2 2026
68 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: ERAS
ERASCA INC
$13.76
−0.94%
9.6%
12.2M$222.6M
2
NASDAQ: ABVX
ABIVAX SA
$83.83
+2.11%
5.9%
1.0M$136.5M
3
NASDAQ: RVMD
REVOLUTION MEDICINES INC
$159.82
−1.76%
5.6%
700K$131.1M
4
NASDAQ: IDYA
IDEAYA BIOSCIENCES INC
$26.49
−3.32%
4.8%
3.0M$111.8M
5
NASDAQ: BNTX
BIONTECH SE
$83.26
−1.89%
4.1%
1.0M$94.4M
6
NASDAQ: VERA
VERA THERAPEUTICS INC
$25.58
−2.37%
4.1%
2.2M$94.4M
7
NASDAQ: TNGX
TANGO THERAPEUTICS INC
$21.89
−1.00%
3.8%
2.9M$89.1M
8
NASDAQ: PRAX
PRAXIS PRECISION MEDICINES I
$305.19
+0.04%
3.7%
260K$87.0M
9
NASDAQ: CLDX
CELLDEX THERAPEUTICS INC NEW
$27.55
−1.75%
3.4%
2.1M$78.1M
10
NASDAQ: DNTH
DIANTHUS THERAPEUTICS INC
$83.98
−3.45%
3.4%
800K$78.0M
11
NASDAQ: CGON
CG ONCOLOGY INC
$80.00
+1.34%
3.1%
1.0M$71.0M
12
NASDAQ: IRON
DISC MEDICINE INC
$77.98
+1.84%
2.8%
875K$64.0M
13
NASDAQ: MAZE
MAZE THERAPEUTICS INC
$31.20
−5.08%
2.5%
1.9M$57.7M
14
NASDAQ: DYN
DYNE THERAPEUTICS INC
$15.87
−0.94%
2.4%
2.5M$56.6M
15
NASDAQ: MLTX
MOONLAKE IMMUNOTHERAPEUTICS
$10.79
−4.09%
2.2%
2.7M$52.1M
16
NASDAQ: OCUL
OCULAR THERAPEUTIX INC
$5.94
−1.33%
2.2%
5.3M$52.0M
17
NASDAQ: DSGN
DESIGN THERAPEUTICS INC
$9.47
−3.76%
1.9%
3.0M$43.4M
18
NASDAQ: OLMA
OLEMA PHARMACEUTICALS INC
$7.06
−2.22%
1.7%
3.2M$40.1M
19
NASDAQ: BLTE
BELITE BIO INC
$156.23
−0.94%
1.7%
250K$38.5M
20
NASDAQ: ACHV
ACHIEVE LIFE SCIENCE INC
$6.14
+1.32%
1.5%
5.4M$35.4M
21
NASDAQ: TRVI
TREVI THERAPEUTICS INC
$13.51
0.00%
1.5%
1.9M$35.1M
22
NASDAQ: COGT
COGENT BIOSCIENCES INC
$27.81
−0.14%
1.5%
900K$34.8M
23
NASDAQ: AVBP
ARRIVENT BIOPHARMA INC
$10.90
+1.96%
1.5%
1.0M$34.7M
24
NASDAQ: CBIO
CRESCENT BIOPHARMA INC.
$12.40
−4.91%
1.5%
1.9M$34.2M
25
NASDAQ: CMPS
COMPASS PATHWAYS PLC
$8.12
+1.75%
1.4%
2.3M$31.8M

Showing 1–25 of 68 positions on this page reported in this 13F.

Sector allocation
  • Healthcare98%
Recent activity · vs 2026-03-31
Bought43
  • AddedERASERASCA INC+9.0%$222.6M
  • AddedABVXABIVAX SA+51.7%$136.5M
  • NewBNTXBIONTECH SE—$94.4M
  • NewVERAVERA THERAPEUTICS INC—$94.4M
  • AddedCLDXCELLDEX THERAPEUTICS INC NEW+367%$78.1M
  • AddedDNTHDIANTHUS THERAPEUTICS INC+100%$78.0M
  • AddedCGONCG ONCOLOGY INC+73.9%$71.0M
  • AddedIRONDISC MEDICINE INC+56.3%$64.0M
  • AddedMAZEMAZE THERAPEUTICS INC+56.7%$57.7M
  • AddedDYNDYNE THERAPEUTICS INC+82.1%$56.6M
Sold39
  • ReducedRVMDREVOLUTION MEDICINES INC−65.0%$131.1M
  • ReducedIDYAIDEAYA BIOSCIENCES INC−13.0%$111.8M
  • ReducedTNGXTANGO THERAPEUTICS INC−5.0%$89.1M
  • ReducedPRAXPRAXIS PRECISION MEDICINES I−8.8%$87.0M
  • ReducedTRVITREVI THERAPEUTICS INC−21.7%$35.1M
  • ReducedIMVTIMMUNOVANT INC−38.1%$25.6M
  • ReducedELVNENLIVEN THERAPEUTICS INC−13.9%$23.6M
  • ReducedRCUSARCUS BIOSCIENCES INC−45.8%$20.0M
  • ReducedIMCRIMMUNOCORE HLDGS PLC−60.0%$19.1M
  • ReducedLBRXLB PHARMACEUTICALS INC−36.1%$19.0M
5%+ Beneficial Ownership Stakes · 4 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
ACHV
Yarrow Bioscience, Inc.
13G10.0% · 2 classes1.0MFiled 16 NOV 2026
2
XLO
Xilio Therapeutics, Inc.
13G10.0%730KFiled 16 NOV 2026
3
TENX
Tenax Therapeutics, Inc.
13G9.9%615KFiled 09 MAR 2026
4
PTN
PALATIN TECHNOLOGIES INC
13G9.9% · 2 classes182KFiled 15 MAY 2026

Showing all 4 disclosed stakes.

Reading Logos Global Management LP’s 13F portfolio

Logos Global Management LP’s $2.3B 13F book is spread across 68 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 48%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are ERAS, ABVX, RVMD, IDYA and BNTX, led by ERASCA INC (ERAS) at 9.6% of the portfolio. The heaviest sector exposure is Healthcare (98%).

What Logos Global Management LP changed last quarter

Between 2026-03-31 and Q2 2026, Logos Global Management LP was roughly balanced between buying and selling: it opened 25 new positions and added to 18 more, while trimming 19 and closing 20 outright. Against a 68-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ERASCA INC (ERAS), and its biggest reduction was REVOLUTION MEDICINES INC (RVMD).

What a 13F does and doesn’t reveal

A 13F captures only Logos Global Management LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Logos Global Management LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Logos Global Management LP's profile on this page is built directly from those filings.

How current is the 13F data on Logos Global Management LP's page?

It reflects Logos Global Management LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Logos Global Management LP files its next quarterly report, this page refreshes automatically.

Can I see Logos Global Management LP's complete list of holdings?

This page highlights Logos Global Management LP's largest positions rather than all 68 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Logos Global Management LP's filings.

Does a 13F show everything Logos Global Management LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Logos Global Management LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Logos Global Management LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.